Literature DB >> 11435603

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.

J Lennerstrand1, K Hertogs, D K Stammers, B A Larder.   

Abstract

Using a large panel of human immunodeficiency virus type 1 site-directed mutants, we have observed a higher correlation than has previously been demonstrated between zidovudine (AZT)-triphosphate resistance data at the reverse transcriptase (RT) level and corresponding viral AZT resistance. This enhanced-resistance effect at the RT level was seen with ATP and to a lesser extent with PP(i) when ATP was added at physiological concentrations. The ATP-dependent mechanism (analogous to pyrophosphorolysis) appears to be dominant in the mutants bearing the D67N and K70R or 69 insertion mutations, whereas the Q151M mutation seems independent of ATP for decreased binding to AZT-triphosphate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435603      PMCID: PMC114451          DOI: 10.1128/JVI.75.15.7202-7205.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

2.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.

Authors:  B A Larder; A Kohli; P Kellam; S D Kemp; M Kronick; R D Henfrey
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

3.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Authors:  P R Meyer; S E Matsuura; A M Mian; A G So; W A Scott
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

4.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

5.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

6.  Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5'-triphosphate sulfurylase.

Authors:  B A Barshop; D T Adamson; D C Vellom; F Rosen; B L Epstein; J E Seegmiller
Journal:  Anal Biochem       Date:  1991-08-15       Impact factor: 3.365

7.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Authors:  S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; S D Kemp; B A Larder
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

9.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Authors:  P Kellam; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  Related functional domains in virus DNA polymerases.

Authors:  B A Larder; S D Kemp; G Darby
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more
  20 in total

1.  Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

Authors:  J Lennerstrand; D K Stammers; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 2.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

Authors:  Johan Lennerstrand; Chung K Chu; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

5.  Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.

Authors:  Emmanuele Crespan; Giada A Locatelli; Reynel Cancio; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Synthesis of Boranoate, Selenoate, and Thioate Analogs of AZTp(4)A and Ap(4)A.

Authors:  Qianwei Han; Stefan G Sarafianos; Eddy Arnold; Michael A Parniak; Barbara L Gaffney; Roger A Jones
Journal:  Tetrahedron       Date:  2009-09-19       Impact factor: 2.457

7.  A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Authors:  Antonio J Acosta-Hoyos; Suzanne E Matsuura; Peter R Meyer; Walter A Scott
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

8.  The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.

Authors:  P P Chamberlain; J Ren; C E Nichols; L Douglas; J Lennerstrand; B A Larder; D I Stuart; D K Stammers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.